Olema Pharmaceuticals

Company OLMA

Last mentioned: Mar 22, 2026

Timeline

  1. Commercial Launch

    Target date for the market entry of palazestrant for ER+ breast cancer treatment.

  2. Institutional Stake Disclosure

    Reports surfaced regarding a significant $122 million position held by a major investor.

  3. Price Target Hike

    Wall Street analysts raised the price target for OLMA to $62.00, citing clinical optimism.

  4. Earnings & SEC Filing

    Olema reported quarterly results and filed an 8-K detailing its financial condition.

Stories mentioning Olema Pharmaceuticals 1

markets Neutral

Olema Pharmaceuticals Surges 242% as $122M Institutional Stake Signals Growth

Olema Pharmaceuticals (OLMA) has delivered a massive 242% return over the past year, fueled by clinical progress in its lead breast cancer candidate, palazestrant. A recent $122 million institutional position has sparked debate over whether the biotech firm still has significant room for growth ahead of a projected 2027 launch.

2 sources